signal transducing adaptor molecule 2Genealiases: Hbp · STAM2A · STAM2B
Q-omics provides the consensus-scored STAM2 profile across patient tissues and cancer cell-line models. STAM2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STAM2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, STAM2 protein abundance shows 24,455 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, THCA, and LUAD as cancer lineages where STAM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STAM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STAM2 survival associations across molecular data types. STAM2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STAM2 RNA expression–survival associations across cancer types. High STAM2 expression shows unfavorable associations in ACC, KIRP, UVM, LGG and HNSC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STAM2 RNA expression.
This table summarizes STAM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for STAM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STAM2 shows lower tumor expression in THCA, KICH, KIRC and LUSC and higher tumor expression in LIHC and CHOL. The THCA box plot shows higher STAM2 RNA expression in normal versus tumor tissue (log2 FC = −0.612, t-test p < 0.001).
This table shows molecular features associated with STAM2 in patient tissues and cancer cell lines. In patient samples, STAM2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, STAM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
